Literature DB >> 32854535

Long-term restoration of corneal sensitivity in neurotrophic keratopathy after rhNGF treatment.

Antonio Di Zazzo1, Giuseppe Varacalli1, Tommaso Mori1, Marco Coassin1.   

Abstract

BACKGROUND: To report the long-term effects of the new rhNGF treatment on corneal sensitivity in patients with. CASES
PRESENTATION: We present three cases of corneal ulcers due to NK that were treated with rhNGF. In each patient wound healing evolution was documented by clinical pictures and corneal sensitivity measured by Cochet-Bonnet aesthesiometry. Best corrected visual acuity and Type I Schirmer test were also assessed neurotrophic keratopathy.All patients healed within 8 weeks and NK showed no recurrences in the mean follow-up period of 35 weeks. Each subject showed a significant increase of corneal sensitivity and tear secretion, with concomitant improvement in visual acuity.
CONCLUSION: Corneal sensitivity, measured by Cochet-Bonnet aesthesiometer, markedly increased in all eyes. Further studies are warranted to demonstrate a possible mechanism of nerve restoration with rhNGF treatment.

Entities:  

Keywords:  Exposure keratopathy; corneal transplantation; persistent corneal epithelial defects; stains

Mesh:

Year:  2020        PMID: 32854535     DOI: 10.1177/1120672120953343

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  5 in total

1.  Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?

Authors:  Alice Bruscolini; Marco Marenco; Giuseppe Maria Albanese; Alessandro Lambiase; Marta Sacchetti
Journal:  Orphanet J Rare Dis       Date:  2022-02-16       Impact factor: 4.123

2.  Tear proteomics reveals the molecular basis of the efficacy of human recombinant nerve growth factor treatment for Neurotrophic Keratopathy.

Authors:  Damiana Pieragostino; Manuela Lanzini; Ilaria Cicalini; Maria Concetta Cufaro; Verena Damiani; Leonardo Mastropasqua; Vincenzo De Laurenzi; Mario Nubile; Paola Lanuti; Giuseppina Bologna; Luca Agnifili; Piero Del Boccio
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

3.  Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.

Authors:  Alice T Epitropoulos; Jamie L Weiss
Journal:  Am J Ophthalmol Case Rep       Date:  2022-07-02

4.  Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up.

Authors:  Salvador García-Delpech; Patricia Udaondo; Alex Samir Fernández-Santodomingo; Damian García-Teillard
Journal:  Case Rep Ophthalmol       Date:  2022-08-31

5.  The Role of Hi-Tech Devices in Assessment of Corneal Healing in Patients with Neurotrophic Keratopathy.

Authors:  Leandro Inferrera; Emanuela Aragona; Adam Wylęgała; Antonio Valastro; Gianluigi Latino; Elisa I Postorino; Romana Gargano; Bogusława Orzechowska-Wylęgała; Edward Wylęgała; Anna M Roszkowska
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.